Abstract:Drug exposure is a key contributor to the safety and efficacy of drugs. It can be defined using human pharmacokinetics (PK) parameters that affect the blood concentration profile of a drug, such as steady-state volume of distribution (VDss), total body clearance (CL), half-life (t½), fraction unbound in plasma (fu) and mean residence time (MRT). In this work, we used molecular structural fingerprints, physicochemical properties, and predicted animal PK data as features to model the human PK parameters VDss, CL, t½, fu and MRT for 1,283 unique compounds. First, we predicted animal PK parameters [VDss, CL, fu] for rats, dogs, and monkeys for 372 unique compounds using molecular structural fingerprints and physicochemical properties. Second, we used Morgan fingerprints, Mordred descriptors and predicted animal PK parameters in a hyperparameter-optimised Random Forest algorithm to predict human PK parameters. When validated using repeated nested cross-validation, human VDss was best predicted with an R of 0.55 and a Geometric Mean Fold Error (GMFE) of 2.09; CL with accuracies of R =0.31 and GMFE=2.43, fu with R =0.61 and GMFE=2.81, MRT with R =0.28 and GMFE=2.49, and t½ with R =0.31 and GMFE=2.46 for models combining Morgan fingerprints, Mordred descriptors and predicted animal PK parameters. We evaluated models with an external test set comprising 315 compounds for VDss (R =0.33 and GMFE=2.58) and CL (R =0.45 and GMFE=1.98). We compared our models with proprietary pharmacokinetic (PK) models from AstraZeneca and found that model predictions were similar with Pearson correlations ranging from 0.77-0.78 for human PK parameters of VDss and fu and 0.46-0.71 for animal (dog and rat) PK parameters of VDss, CL and fu. To the best of our knowledge, this is the first work that publicly releases PK models on par with industry-standard models. Early assessment and integration of predicted PK properties are crucial, such as in DMTA cycles, which is possible with models in this study based on the input of only chemical structures. We developed a webhosted application PKSmart ( ) which users can access using a web browser with all code also downloadable for local use.

PK/DB: database for pharmacokinetic properties and predictive in silico ADME models

PK-DB: pharmacokinetics database for individualized and stratified computational modeling

Adme-Ap: A Database of Adme Associated Proteins

ADMET Evaluation in Drug Discovery. 11. PharmacoKinetics Knowledge Base (PKKB): A Comprehensive Database of Pharmacokinetic and Toxic Properties for Drugs.

Recent Advances in the Prediction of Pharmacokinetics Properties in Drug Design Studies: A Review

PKSmart: An Open-Source Computational Model to Predict Pharmacokinetics of Small Molecules

Estimating human ADME properties, pharmacokinetic parameters and likely clinical dose in drug discovery

Drug ADME‐associated Protein Database As a Resource for Facilitating Pharmacogenomics Research

SwissADME and pkCSM Webservers Predictors: an integrated Online Platform for Accurate and Comprehensive Predictions for In Silico ADME/T Properties of Artemisinin and its Derivatives

Information of ADME-Associated Proteins and Potential Application for Pharmacogenetic Prediction of Drug Responses

pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures

Using in vitro ADME data for lead compound selection: An emphasis on PAMPA pH 5 permeability and oral bioavailability

Open access in silico tools to predict the ADMET profiling of drug candidates

Pharmacokinetics Profiler (PhaKinPro): Model Development, Validation, and Implementation as a Web Tool for Triaging Compounds with Undesired Pharmacokinetics Profiles

Model-based Target Pharmacology Assessment (mTPA): An Approach Using PBPK/PD Modeling and Machine Learning to Design Medicinal Chemistry and DMPK Strategies in Early Drug Discovery

PhRMA CPCDC Initiative on Predictive Models of Human Pharmacokinetics, Part 1: Goals, Properties of the Phrma Dataset, and Comparison with Literature Datasets

In silico ADME-Tox modeling: progress and prospects

ADME evaluation in drug discovery. 7. Prediction of oral absorption by correlation and classification.

A fully automatic tool for development of population pharmacokinetic models

PKAD: a database of experimentally measured pKa values of ionizable groups in proteins

PBPK modeling and simulation in drug research and development